BioCryst Pharmaceuticals Aktie - Fundamentalanalyse - Dividendenrendite KGV

BioCryst Pharmaceuticals (ISIN: US09058V1035, WKN: 896047) Kursdatum: 20.04.2018 Kurs: 4,910 USD
Beschreibung Daten
Symbol BCRX
Marktkapitalisierung 414.654.400,00 USD
Land Vereinigte Staaten von Amerika
Indizes NASDAQ Comp.
Sektor Pharma
Rohdaten nach US GAAP in Millionen USD
Aktiensplits
Internet www.biocryst.com
Letztes Bilanz Update 12.03.2018

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 20.04.2018
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
-10,00 -10,08 0,00% -36,95 0,55 -6,30 16,46 421,40

Firmenbeschreibung

Note 10 — Quarterly Financial Information (Unaudited)       First   Second   Third   Fourth 2015 Quarters                                 Revenues   $ 6,826     $ 25,842     $ 10,987     $ 4,602   Net (Loss) Income     (15,164 )     4,901       (14,621 )     (18,135 ) Basic net (loss) income per share     (0.21 )     0.07       (0.20 )     (0.25 ) Diluted net (loss) income per share     (0.21 )     0.06       (0.20 )     (0.25 ) 2014 Quarters                                 Revenues   $ 3,458     $ 1,466     $ 3,238     $ 5,446   Net Loss     (10,137 )     (14,649 )     (8,731 )     (11,672 ) Basic and diluted net loss per share     (0.17 )     (0.23 )     (0.12 )     (0.16 )

Die Finanzoo GmbH übernimmt keine Haftung für die Richtigkeit der Angaben! Alle Angaben sind ohne Gewähr. Quellen: www.bundesanzeiger.de, www.sec.gov, www.biocryst.com